Document is current

Article History

Received: 21 October 2024

Accepted: 15 December 2024

First Online: 7 January 2025

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: This practice guideline was approved by the Board of Directors of the EANM, SNMMI, EANO and PET/RANO Working Group.

: AV: has received honoraria for lectures and advisory board participation from Curium, Eisai, General Electrics and Novartis. NT: no disclosures FC: no disclosures. SMC: no disclosures JF: has received honoraria for lectures and consultations from the following for-profit companies: Novartis, Seagen, Sanova, Servier. NG: has received honoraria for lectures from Blue Earth Diagnostics and for advisory board participation from Telix Pharmaceuticals and Servier, and for consultancy services from Telix Pharmaceuticals. JG: has received honoraria for consultation and advisory board participation from Seagan, Brain Lab, research support from Zeiss. EG: has received honoraria for consultation and advisory board participation from AAA/Novartis, Curium/LMI, General Electric, Keosys and Pfizer. RH: has received consultation fees for Telix, Servier, and Nuvation Bio and scientific advisory for Vysioneer,. DJ: has received honoraria for consultation and advisory board participation from Telix Pharmaceuticals, Cellectar and Novartis. IL: no disclosures. ELR: has received a research grant from BMS, and honoraria for advisory board participation from Astra Zeneca, Bayer, Bioderix, Janssen, Leo Pharma, Pfizer, Pierre Fabre, Seagen and Servier. SCS: has received honoraria and consulting fees from Chimerix, Servier, CeCaVa, Miltenyi, Roche and research support from Apollomics and Blue Earth Diagnostics. MJVdB: has received honoraria for consultation and advisory board participation from Servier, Anheart Therapeutics, Fore Biotherapeutics, Genenta, Roche, Chimerix, Mundipharm, Boehringer and Incyte, and research support from Boehringer Ingelheim. DVW: no disclosures. MAV: has received research support to his hospital from NIH, DeNovo Pharma, Infuseon, Therapeutics, Oncosynergy; and honoraria from Servier Pharma, and Biodexa Pharma. PYW: has received research support from Astra Zeneca, Black Diamond, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Global Coalition For Adaptive Research, Kazia, MediciNova, Merck, Novartis, Quadriga, Servier, and VBI Vaccines and honoraria for consultation and advisory board participation from Anheart, Astra Zeneca, Black Diamond, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Kintara, Merck, Mundipharma, Novartis, Novocure, Prelude Therapeutics, Sagimet, Sapience, Servier, Symbio, Tango, Telix, VBI Vaccines. NLA: has received honoraria for lectures, consultation or advisory board participation from Novartis, Advanced Accelerator Applications, Telix Pharmaceuticals, OncLive, Medsir and Servier, and research funding from Novocure and Telix Pharmaceuticals. MP: has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape. IL: has received honoraria for lectures and consultations from Telix Pharmaceuticals and Ribocure.